Colgate Palmolive and Procter and Gamble side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Colgate Palmolive | Procter and Gamble |
|---|---|---|
| Phase 1 | 00% | 00% |
| Phase 2 | Colgate Palmolive: 1 of its 35 programs at phase 2
| Procter and Gamble: 1 of its 8 programs at phase 2
|
| Phase 3 | Colgate Palmolive: 25 of its 35 programs at phase 3
and 20 more — sign in to see them all | 00% |
| Approved, new studies | Colgate Palmolive: 9 of its 35 programs at approved, new studies
and 4 more — sign in to see them all | Procter and Gamble: 7 of its 8 programs at approved, new studies
and 2 more — sign in to see them all |
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Colgate Palmolive9 readouts · 9 phase 3 | Colgate Palmolive, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3
| Colgate Palmolive, Dec ’26: 2 programs whose next study reaches primary completion, 2 in phase 3
| Colgate Palmolive, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | · | Colgate Palmolive, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Colgate Palmolive, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | · | · | Colgate Palmolive, Sep ’27: 3 programs whose next study reaches primary completion, 3 in phase 3
| · |
| Procter and Gamble0 readouts · 0 phase 3 | · | · | · | · | · | · | · | · | · | · | · | · |
Changed in the last 90 days
Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Colgate Palmolive
New programs 8
- oil-balancing sunscreenapproved, new study · first study · Nov 6 · Acne Vulgaris
- 0.09% CPC + Zinc Lactate Mouthwashapproved, new study · first study · Oct 7
- Vitamin C toothpastephase 2 · first study · Oct 6 · Tooth Discoloration
- 0.45% SnF HW with NaF (1450 F)phase 3 · first study · Sep 21 · Dental Plaque
- Silica Free Meridolphase 3 · first study · Sep 21 · Gingivitis
- Prevident 5000ppm Booster Plus Toothpasteapproved, new study · first study · Sep 2
Colgate Palmolive: new programs in 90 days
- oil-balancing sunscreenapproved, new study · first study · Nov 6
- 0.09% CPC + Zinc Lactate Mouthwashapproved, new study · first study · Oct 7
- Vitamin C toothpastephase 2 · first study · Oct 6
- 0.45% SnF HW with NaF (1450 F)phase 3 · first study · Sep 21
- Silica Free Meridolphase 3 · first study · Sep 21
and 3 more — sign in to see them all
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Procter and Gamble
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Where they overlap
Conditions where at least two of them have programs: 9 in all. A program counts in each condition its studies name most.
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
No gene two of them both target, among the programs whose target is known.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.